3月24日 - ** 总部位于佛罗里达州的药物开发商MIRA Pharmaceuticals MIRA.O股价下跌8.6%,至1.17美元
** 同意以股票交易的方式收购特拉华州私营企业SKNY Pharmaceuticals,以增加实验性减肥候选药物——监管文件 (link)
** SKNY-1是一种临床前研发的减肥和戒烟口服实验药物
** SKNY将在交易结束时以现金或资产形式出资500万美元
** MIRA在过去12个月中略有增长
(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.